title: Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
abstract: BACKGROUND
  The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). This report describes the quality of life (QoL) and updated PFS analyses from this study.
  
  
  METHODS
  Chinese patients ≥ 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). The primary efficacy end point was PFS; QoL was assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire, Trial Outcome Index (TOI) and Lung Cancer Subscale (LCS).
  
  
  RESULTS
  Patients receiving erlotinib experienced clinically relevant improvements in QoL compared with the chemotherapy group in total FACT-L, TOI and LCS (P < 0.0001 for all scales). Erlotinib scored better than chemotherapy for all FACT-L subscales from baseline to cycles 2 and 4 (non-significant). In the updated analysis, PFS was significantly longer for erlotinib than chemotherapy (median PFS 13.7 versus 4.6 months; HR = 0.164, 95% CI = 0.105-0.256; P < 0.0001), which was similar to the previously reported primary analysis.
  
  
  CONCLUSIONS
  Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC.
authors: Tumor Medicine, The Cancer Hospital of Harbin Medical University, Harbin, China.
authors: G
authors: G
authors: Chen
authors: J
authors: J
authors: Feng
authors: C
authors: C
authors: Zhou
authors: Y-L
authors: YL
authors: Wu
authors: X-Q
authors: XQ
authors: Liu
authors: C
authors: C
authors: Wang
authors: S
authors: S
authors: Zhang
authors: J
authors: J
authors: Wang
authors: S
authors: S
authors: Zhou
authors: S
authors: S
authors: Ren
authors: S
authors: S
authors: Lu
authors: L
authors: L
authors: Zhang
authors: C-P
authors: CP
authors: Hu
authors: C
authors: C
authors: Hu
authors: Y
authors: Y
authors: Luo
authors: L
authors: L
authors: Chen
authors: M
authors: M
authors: Ye
authors: J
authors: J
authors: Huang
authors: X
authors: X
authors: Zhi
authors: Y
authors: Y
authors: Zhang
authors: Q
authors: Q
authors: Xiu
authors: J
authors: J
authors: Ma
authors: L
authors: L
authors: Zhang
authors: C
authors: C
authors: You
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000523:psychology; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011788:Quality of Life / Q000523:psychology; D011799:Quinazolines / Q000008:administration & dosage; D011795:Surveys and Questionnaires
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGFR mutations; chemotherapy; erlotinib; non-small-cell lung cancer (NSCLC); quality of life (QoL)